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Cleavage of the disulfide bond linking the heavy and the light chains of tetanus toxin is necessary for its inhibitory action 
on exocytotic release of catecholamines from permeabilized chromaffin cells [(1989) FEBS Lett. 242, 245-248; (1989) J. 
Neurochem., in press]. The related botulinum A toxin also consists of a heavy and a light chain linked by a disulfide 
bond. The actions of both neurotoxins on exocytosis were presently compared using streptolysin 0-permeabilized bovine 
adrenal chromaffin cells. Botulinum A toxin inhibited Ca*+-stimulated catecholamine release from these cells. Addition 
of dithiothreitol owered the effective doses to values below 5 nM. Under the same conditions, the effective doses of teta- 
nus toxin were decreased by a factor of five. This indicates that the interchain S-S bond of botulinum A toxin must 
also be split before the neurotoxin can exert its effect on exocytosis. 
Botulinum A toxin; Chain separation; Reduction; Exocytosis; (Chromaflin cell) 
1. INTRODUCTION 
The clostridial neurotoxins tetanus toxin (Tetx) 
and botulinum toxin A (Botx A) are members of a 
family of closely related high molecular mass pro- 
teins. The 150 kDa proteins consist of a heavy and 
a light chain covalently linked by a disulfide bond. 
They belong to the most poisonous substances 
known. Their main target is the central (Tetx) or 
the peripheral (Botx A) nervous system where they 
act as very potent inhibitors of transmitter elease 
[3-51. Besides their well-known effects on 
neurons, Tetx and Botx A have recently been 
reported to inhibit exocytosis from adrenal 
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medullary chromaffin cells when injected in- 
tracellularly [6]. Similar results were obtained 
when chromaffin cells were treated extracellularly 
with large amounts of various botulinurn 
neurotoxins, whereas Tetx was ineffective under 
these conditions [7]. 
Using permeabilized chromaffin cells, the in- 
tracellular effects on exocytosis by these neurotox- 
ins can be studied more directly. In such 
preparations the internalization process is bypass- 
ed and defined doses can be applied. Recently, the 
inhibitory action of Tetx on exocytosis from 
digitonin- [8] and streptolysin 0 (SLO)- 
permeabilized chromaffin cells has been described 
[1,2]. Furthermore, the effect of Tetx can be 
augmented by addition of dithiothreitol (DTT), 
which reduces the interchain disulfide bond be- 
tween the heavy and light chains of Tetx [1,2]. 
Even the purified light chain alone has been found 
to inhibit exocytosis [l]. The present study was 
undertaken to determine whether Botx A requires 
activation via a similar process to that for Tetx 
before becoming effective within the cell. 
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2. EXPERIMENTAL 
2.1. Materials 
Tetx, Botx A and Botx B were a generous gift from U. Weller 
and E. Habermann (Rudolf Buchheim-Institut fur Phar- 
makologie, Giessen, FRG). The LDso in mice was 2 ng/kg for 
Tetx, and 3 ng/kg for both botulinum toxins. Streptolysin 0 
was kindly provided by S. Bhakdi (Institut filr Mikrobiologie, 
Giessen). Botx A antitoxin (horse, 750 W/ml) was obtained 
from Behring Werke (Marburg), collagenase (0.7 IU/mg) from 
Serva (Heidelberg), collagen (rat tail) and cytosine arabinoside 
from Sigma (Muncher& and DMEM and fetal calf serum from 
Seromed, Biochrom KG (Berlin, Germany). 
2.2. Cell cultures 
Chromaffin cells from bovine adrenal medulla were prepared 
as described [9]. Briefly, fresh adrenals were dissected free of 
fat and connective tissue and immediately rinsed free of blood 
by several retrograde injections of ice-cold buffer I (mM: 150 
NaCl, 5 KCI, 10 glucose, 10 Hepes, pH 7.4, supplemented with 
50 IU penicillin, 50 pg/ml streptomycin and 0.25 pg/ml 
fungizone). The adrenals were transported to the laboratory on 
ice. The majority of red blood cells were removed by further 
perfusion as described above. Subsequently, whole glands were 
incubated with collagenase (O.OSW in buffer I supplemented 
with 0.5% BSA) for 1 h at 37°C. The medullae were removed 
and incubated with collagenase for a further 1 h. The resulting 
cell suspension was filtered through a nylon mesh (250 /tm) and 
washed several times with buffer I containing 2% BSA. The 
cells were suspended in culture medium (DMEM) containing 
10% fetal calf serum and 5 FM cytosine arabinoside. They were 
plated on precoated (rat tail collagen, 20 pg/ml) wells at a den- 
sity of 3 x 10s cells. 
Rat pheochromocytoma cells (PCl2) kindly provided by H. 
Thoenen (Max-Planck-Institut filr Psychiatric, Martinsried) 
were cultivated as stated earlier [lo]. 
2.3. Assay for exocytosis 
Adrenal chromaffin or PC12 cells were preloaded with 
tritiated noradrenaline or dopamine [ 1,2,10,11]. After several 
washes with Ca”-free buffer II (mM: 140 NaCl, 4.6 KCl, 1.2 
KH2P04, 1.2 MgSO.+, 0.5 ascorbic acid, 15 Pipes, pH 7.2), buf- 
fer III (mM: 150 NaCl, 10 Pipes, 1 EGTA, pH 7.2) and KG buf- 
fer (mM: 150 K+ glutamate, 10 Pipes, 0.5 EGTA, 5 NTA, pH 
7.2), cells were permeabilized with SLO (30 HI-l/ml for adrenal 
chromaffin cells or 60 HU/ml for PC12 cells) in KG buffer sup- 
plemented with 0.1% BSA, 2 mM Mg’+/ATP and 1 mM Mg*+ 
free, either on ice (PC12) or at 37°C for 2 min [2,11]. The buf- 
fer was then replaced with a fresh one containing the neurotoxin 
preparations to be tested. After incubation for 25 min at 37’C, 
cells were challenged for 10 min with KG buffer containing the 
indicated amounts of free Ca’+. The buffer was either com- 
pletely replaced by fresh buffer containing the indicated 
amounts of free Ca2+ (adrenal chromaffin cells) or Ca*+ was 
added to obtain the final free Ca*+ concentration (PC12 cells). 
The [‘Hlcatecholamines released were estimated in the superna- 
tant and in cells after lysis in 0.2(rlo SDS [ 1,2, lo]. Values (mean 
of duplicate or triplicate determinations) are expressed as % of 
the radioactivity present at the beginning of stimulation. Free 
Ca’+ concentrations were calculated using the stability con- 
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stants given in [12] and were routinely monitored by a 
Cazf-sensitive electrode [ 131. 
3. RESULTS 
Adrenal chromaffin cells take up 3-5% of the 
radioactive dopamine or noradrenaline offered. 
When permeabilized with SLO and incubated for 
25 min at 37”C, equal amounts (5%) of 
[3H]noradrenaline or [3H]dopamine can be re- 
leased by micromolar concentrations of free Ca’+ 
(fig. 1). Incubation of permeabilized cells with Botx 
A for 25 min at 37 “C reduces both 
[3H]noradrenaline and [3H]dopamine release 
evoked by 30 ,uM free Ca’+ (fig. 1). The effects of 
Botx A are specific because they can be overcome 
by boiling or preincubating the toxin with antitox- 
in. The- antitoxin itself has no effect 
Ca’+-stimulated release (fig. 1). 
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Fig.1. Inhibitory effect of Botx A on Ca’+-stimulated 
[‘Hlcatecholamine release from SLO-permeabilized adrenal 
chromaffin cells. Adrenal chromaffin cells were preloaded with 
either [‘Hlnoradrenaline (A) or [‘Hldopamine (B) and 
permeabilized with SLO as given in section 2. The cells were 
incubated for 25 min at 37°C with antitoxin (7.5 U/ml), Botx 
A (4.2 nM), Botx A (4.2 nM) + antitoxin (7.5 U/ml) or Botx A 
(4.2 nM) previously heated for 15 min to 95°C as indicated. 
Before use all toxin dilutions were incubated for 2 h at room 
temperature which is necessary for the inactivation of Botx A 
in the antitoxin-containing sample. The incubation buffer was 
exchanged for fresh one containing 30,~M free Ca*+. Values 
obtained in two separate experiments are means of three 
samples + SD. 
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The inhibitory action of Botx A increases with 
incubation time. More than 10 min are required to 
affect Ca2+-induced exocytosis (not shown). 
Fig.2 gives a dose-response curve for the in- 
hibitory action of Botx A on exocytosis in the 
presence or absence of DTT. Although DTT is not 
absolutely required for the effects of Botx A, it 
drastically reduces the effective dose of this 
neurotoxin to values below 5 nM final concentra- 
tion (fig.2). Inhibition by Botx A, even at doses up 
to 100 nM and in the presence of DTT, is never 
complete and does not exceed 60-70% (not 
shown). Varying the free Ca2+ concentration dur- 
ing stimulation does not substantially alter the in- 
hibition by Botx A (not shown). 
Parallel experiments have been performed with 
Tetx. Again the presence of DTT greatly reduces 
the effective dose of this neurotoxin (fig.3). 
However, compared to Botx A, greater amounts of 
Tetx are required to affect exocytosis (figs 2,3). 
The complete inhibition observed with Tetx con- 
trasts with the partial inhibition obtained with 
Botx A under the same conditions (see figs 2,3). 
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Fig.2. DTT increases the inhibitory effect of Botx A on 
exocytosis from SLO-permeabilized adrenal chromaffin cells. 
[‘H]Noradrenaline-preloaded and SLO-permeabilized adrenal 
chromaffin cells were incubated with various amounts of Botx 
A toxin (abscissa) in either the absence (m) or presence 
(M) of 1 mM DTT. Ordinate: [3H]noradrenaline released 
due to stimulation with 30 pM free Cazf . Release in the absence 
of Cazf was approx. 4% under both conditions. Values are 
means of three determinations + SD. 
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Fig.3. DTT increases the inhibitory effect of Tetx on exocytosis 
from SLO-permeabilized adrenal chromaffin cells. The 
procedure followed that given in fig.2. After incubation of cells 
with the given (abscissa) amounts of Tetx in either the absence 
(M) or presence (M) of 1 mM DTT, cells were 
stimulated with 35 /rM free Ca’+. Values are means of two 
determinations. Release in the absence of Ca*+ (4.8%) was 
subtracted. 
Experiments have been also performed with 
SLO-permeabilized PC12 cells. These cells exhibit 
roughly the same sensitivity towards Tetx as 
adrenal medullary chromaffin cells [1,2]. 
However, catecholamine release from PC12 as op- 
posed to chromaffin cells is only affected by 
20-times higher concentrations of Botx A even 
when DTT is present (table 1, cf. fig.2). 
Table 1 
Inhibitory effect of Botx A on Ca’+-stimulated [3H]dopamine 
release from SLO-permeabilized PC12 cells 
[‘H]Dopamine release (o/o) 
stimulated by Ca*+ (20 FM) 
Control 19.8 
Botx A 70 nM 10.9 
14 nM 17.6 
2.8 nM 18.7 
[3H]Dopamine-preloaded cells were incubated with SLO at 0°C 
for 2 min [l]. The medium was replaced by fresh buffer 
supplemented with Botx A and 1 mM DTT. After 20 min at 
37°C the cells were stimulated with 20 PM free Ca2+ for 10 min. 
Values are means of two determinations. Release in the absence 
of Ca*+ (14%) was subtracted 
25 
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4. DISCUSSION 
It has been recognized that Botx A as well as 
Tetx does not solely affect the secretory process of 
neurons. When applied extracellularly, Botx A, B 
and D, but not Tetx, inhibit exocytosis from 
chromaffin cells [7,14]. The sensitivity of adrenal 
chromaffin cells to Botx A can be increased by 
pretreating the cells with a ganglioside mixture 
which mimicks the ganglioside pattern of the 
neuronal plasma membrane. After this treatment, 
the cells even become sensitive to Tetx [ 151. The 
difference in sensitivity between nerve cells [16] 
and pretreated [15] or untreated [7] adrenal 
chromaffin cells towards clostridial neurotoxins 
may be due to variations in the uptake of ex- 
tracellularly applied neurotoxins by these cells. 
When directly applied to the cytosol by injection 
[6] or through large pores in the plasma membrane 
([ 1,2,8], this paper) both Tetx [1,2,6,8] and Botx A 
([6], this paper) inhibit the Ca’+-stimulated ex- 
ocytosis from chromaffin cells. Thus, Tetx and 
Botx A interfere with steps during exocytosis 
which are common to neurons and chromaffin 
cells and occur after the intracellular rise of Ca’+. 
The intracellular actions of Botx A and Tetx are 
difficult to analyze when applied extracellularly or 
injected into single cells. SLO inserts defined pores 
large enough for the free passage of proteins into 
the plasma membrane [17,18]. In SLO- 
permeabilized adrenal medullary chromaffin or 
PC12 cells, the efficacy of Tetx [1,2] and Botx A 
(this paper) can be compared more directly. The 
inhibitory action of Botx A is greatly augmented 
under reducing conditions, i.e. by addition of 
DTT. This indicates that the S-S bond which links 
the heavy and the light chains must be broken 
before exocytosis can be inhibited. For Tetx the 
same holds true ([2], this paper) and, after chain 
separation, the light chain alone can inhibit ex- 
ocytosis [ 11. 
Besides the generally used ‘two-chain’ form, the 
clostridial neurotoxins also exist in a ‘single-chain’ 
form where the light and heavy chains are linked 
by a peptide bond in addition to the disulfide bond 
[3-51. When subjected to SDS-PAGE under 
reducing conditions, these forms cannot be 
separated into a light and a heavy chain. Ac- 
cordingly, even in the presence of DTT, single- 
chain Tetx does not inhibit exocytosis from per- 
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meabilized chromaffin cells [l]. A preparation of 
Botx B, which proved to be in single-chain form 
when subjected to SDS-PAGE, similarly did not 
affect catecholamine release from permeabilized 
chromaffin cells (unpublished). 
When applied extracellularly, the single-chain 
form of Botx B is also less effective as compared 
to the two-chain form in Aplysia neurons and 
mouse hemidiaphragm [19]. The same applies for 
the single-chain of Tetx when tested in primary 
cultures of mouse brain and in vivo [20]. 
At present, it is not known whether intracellular- 
ly applied Tetx light chain alone inhibits exocytosis 
from neurons as it does in permeabilized adrenal 
chromaffin cells [l]. In contrast, the light chain of 
Botx A, when injected into Aplysia neurons, has 
no effect. In these neurons both the heavy and the 
light chain of Botx A must be present to inhibit 
transmitter release [21]. Further experiments will 
show whether the light chain of Botx A alone or a 
combination of both heavy and light chains is 
responsible for the inhibition of exocytosis from 
chromaffin cells. It is also unclear whether the 
light chain of Tetx alone inhibit exocytosis when 
injected into neurons. Such experiments should 
provide further information as to whether Tetx 
and Botx A act via a different molecular 
mechanism. Otherwise different mechanisms of 
exocytosis must be assumed to operate in en- 
docrine cells and neurons. 
The pharmacological differences between the ac- 
tions of Tetx and Botx A have been attributed to 
different plasma membrane receptors involved in 
the internalization of both toxins leading to the 
same intracellular action [22]. A similar molecular 
mechanism for the action of Tetx and Botx A 
within the cells has been predicted from their 
primary structure [23]. However, from studies us- 
ing mouse hemidiaphragm, different effects of 
Tetx and Botx A have been deduced [24]. Ex- 
periments with permeabilized chromaffin cells sup- 
port the latter conclusion: whereas Botx A gives 
rise to incomplete inhibition of Ca’+-stimulated 
exocytosis ([6,7], this paper) Tetx fully blocks this 
cellular response ([1,6,8], this paper). The ob- 
served differences in effective doses of Tetx and 
Botx A also constitute evidence against the 
assumption of a fully identical mechanism of in- 
tracellular action. 
Clostridial neurotoxins will become valuable 
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tools to define single steps of cellular pathways 
connecting the rise in intracellular Ca2+ concentra- 
tion to fusion of the vesicular and plasma mem- 
brane. Such stepwise analysis may eventually lead 
to an understanding of the underlying molecular 
mechanisms. 
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